Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
Status:
Not yet recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 investigational study to assess the safety and preliminary efficacy of oral
gallium maltolate (GaM) in participants with relapsed glioblastoma (GBM).